Filing Details
Kalaris Therapeutics, Inc. (NASDAQ:KLRS) filed a Form 8-K with the Securities and Exchange Commission on August 11, 2026, disclosing a material event.
8k filedNASDAQ:KLRS
Kalaris Therapeutics, Inc. (KLRS) Reports Material Event to SEC
Kalaris Therapeutics, Inc. (NASDAQ:KLRS) filed a Form 8-K with the Securities and Exchange Commission on August 11, 2026, disclosing a material event.
At publication ·
What changed
Kalaris Therapeutics, Inc. (NASDAQ:KLRS) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) filed a Form 8-K with the SEC on August 11, 2026, disclosing a material event that shareholders should be aware of.
- The company's stock trades at $3.97 with a market capitalization of $157.3 million.
- The article does not specify the nature of the material event, which could involve leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance.
Market Context
Kalaris Therapeutics, Inc.'s stock currently trades at $3.97 with a market capitalization of $157.3M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Kalaris Therapeutics, Inc.'s stock.
All SEC filings for Kalaris Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View KLRS Stock Page
Frequently Asked Questions
Where can I read KLRS's SEC filings?
Browse all filings on our KLRS SEC filings page.
What types of SEC filings does Kalaris Therapeutics, Inc. file?
Public companies like Kalaris Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.